Hormonal
Myostatin inhibition via antibody administration significantly increases muscle mass and strength in aged animal models, representing a promising therapeutic strategy for sarcopenia.
This paper highlights myostatin inhibition as a promising drug target for sarcopenia, showing significant muscle gains in aged mice. However, this is not a current consumer intervention. For now, resistance training combined with amino acid supplementation remains the best practical strategy to prevent age-related muscle loss.
Myostatin inhibition seems to be the most interesting strategy for attenuating sarcopenia other than resistance training with amino acid supplementation. ... treatment with a mouse chimera of antihuman myostatin antibody ... elicited a significant increase in muscle mass and in running performance ... a lower dose of this anti-human myostatin antibody (10 mg/Kg) significantly increased the fiber cross-sectional area (by 12%) and in situ muscle force (by 35%) of aged mice (21 mo old).
Why this rating
Evidence is derived from animal studies (mice/rats) and in vitro mechanisms; human clinical data is not provided in this review.
Source
Sarcopenia and Age-Related Endocrine Function
Kunihiro Sakuma et al. · International Journal of Endocrinology · 2012
DOI 10.1155/2012/127362
More from this paper
- Resistance training combined with amino acid supplementation is the most effective current strategy to prevent age-related muscle wasting and weakness.Strong
- Testosterone supplementation in elderly men increases muscle mass and strength but carries significant side effects, including sleep apnea, thrombotic complications, and prostate cancer risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →